Vessel normalization through anti-VEGF agents improves perfusion and more efficient local delivery of oxygen, decreases vascular leakiness, and reduces intratumoral hypoxia improving pericyte recruitment (Jain, 2001; Huang et al., 2012) allowing drug delivery and immune cell infiltration, and increasing the sensitivity of the tumor cells to radiation and chemotherapy. This evidence concerns the gene VEGFA and neoplasm.